Autopsy report · NCT02480010
A Study of Pertuzumab in Participants With Prostate Cancer
Cause of deathOther
“The study was terminated at the time of interim analysis since none of the participants showed a PSA response.”
Life of this trial
- Registered 11 years 9 months after it had already started.
- Ran for about 2 years before it stopped.
- 68 participants enrolled.
- Results were posted on the registry 10 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Conditions
- Prostate Cancer
- Interventions
- Pertuzumab
- Participants
- 68
- Sites
- 11
- Countries
- France, Germany, Italy, Netherlands, Spain, United Kingdom
Trials that died the same way
- Study of Pemetrexed for Second-Line Pancreas Cancer
“At interim analysis the study did not meet the response criteria to continue” - Adherence to Antidepressant Treatment in Subjects With Depression
“The study was terminated early based on the planned interim analysis that did not meet criteria for continuation.” - Study Evaluating PPM-204 In Subjects With Type 2 Diabetes
“Study terminated as a result of interim analysis not meeting predetermined criteria.” - Effect of Enzymes on Dental Biofilm Accumulation in Healthy Individuals
“The study was terminated after interim data analysis” - A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
“This study was terminated after a pre-specified interim analysis. Please see Detailed Study Description for further information.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.